{"id":14527,"date":"2012-02-01T15:30:00","date_gmt":"2012-02-01T14:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/roche-aumenta-lutile-netto-nel-2011-del-7-fatturato-in-italia-cala-a-9566-mln-38-aa\/"},"modified":"2012-02-01T15:30:00","modified_gmt":"2012-02-01T14:30:00","slug":"roche-aumenta-lutile-netto-nel-2011-del-7-fatturato-in-italia-cala-a-9566-mln-38-aa","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/roche-aumenta-lutile-netto-nel-2011-del-7-fatturato-in-italia-cala-a-9566-mln-38-aa\/","title":{"rendered":"Roche increases 2011 net income by 7%. Turnover in Italy drops to \u20ac956.6m (-3.8% y\/y)"},"content":{"rendered":"<p style=\"line-height: normal; margin: 0cm 0cm 0pt; background: white; mso-outline-level: 1\" class=\"MsoNormal\"><strong><span style=\"font-family: &quot;Trebuchet MS&quot;,&quot;sans-serif&quot;; color: #003882; font-size: 12pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt; mso-fareast-language: IT\">Roche: in 2011 turnover in Italy falls to 956.6 million (-3.8% y\/y)<\/p>\n<p><\/span><\/strong><\/p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0pt; background: white\" class=\"MsoNormal\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; font-size: 9pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><\/p>\n<p>&nbsp;<\/p>\n<p><\/span><\/p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0pt; background: white; tab-stops: 45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt\" class=\"MsoNormal\"><font size=\"3\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\">MILAN (MF-DJ)\u2013During 2011, Roche recorded total turnover in Italy of 956.6 million euros (-3.8% y\/y), confirming its position as 3* company in the pharmaceutical sector and 1* in the hospital sector. <\/span><span style=\"font-family: &quot;Courier New&quot;; color: black; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><\/p>\n<p><\/span><\/font><\/p>\n<p style=\"line-height: normal; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\" class=\"MsoNormal\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><font size=\"3\">As expected, explains a note, the financial year that has just ended was a year of transition for the company, which was affected by the problems of the pharmaceutical sector in Italy, mainly related to bureaucracy, delays in payments and in the registration of drugs, and the absence of a clear and stable policy for the sector, which primarily penalize those who carry out research and produce innovation. <\/p>\n<p><\/font><\/span><\/p>\n<p style=\"line-height: normal; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\" class=\"MsoNormal\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><font size=\"3\">The latest maneuver in July will cause companies to bear one third of the deficit of the regions relating to hospital pharmaceutical expenditure - in proportion to their hospital turnover. A provision considered by many to be unfair and which does not address the real, widely shared problem of under-financing of hospital costs in our country. <\/p>\n<p><\/font><\/span><\/p>\n<p style=\"line-height: normal; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\" class=\"MsoNormal\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><font size=\"3\">The manoeuvre, continues the note, takes the form of a real &quot;tax on innovation&quot; which in a certain sense removes responsibility from those regional administrations which already today regularly exceed their budget. At the same time, it does not reward virtuous behavior. Among other things, it punishes the companies that are most committed to innovation, risking discouraging investments in Research and Development. <\/p>\n<p><\/font><\/span><\/p>\n<p style=\"line-height: normal; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\" class=\"MsoNormal\"><span","protected":false},"excerpt":{"rendered":"<p>Roche: in 2011 fatturato in Italia cala a 956,6 mln (-3,8% a\/a) &nbsp; MILANO (MF-DJ)&#8211;Nel corso del 2011, Roche ha registrato in Italia un fatturato complessivo di 956,6 milioni di euro (-3,8% a\/a), confermandosi 3* azienda del settore farmaceutico e 1* in ospedale. Come da attese, spiega una nota, l&#8217;esercizio che si e&#8217; appena concluso &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-14527","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=14527"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14527\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=14527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=14527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=14527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}